Alkem's consolidated PAT fell 22.0% YoY to Rs520.98 Cr in Q1 FY27 (quarter ended 30 June 2026), even as revenue from operations grew a healthy 10.95% YoY to Rs3,740.15 Cr and consolidated PBT was essentially flat (Rs771.99 Cr vs Rs771.01 Cr a year earlier, +0.1%). The gap between flat pretax profit and a sharply lower bottom line is explained almost entirely by tax: the effective tax rate jumped to 32.5% this quarter from 13.3% in Q1 FY26, after the company moved to the new tax regime under Section 115BAA of the Income-tax Act (Note 4) - deferred tax is now recognised at the new regime's enacted rates, ending the more favourable MAT-credit treatment used earlier. Standalone PAT of Rs569.98 Cr was down a smaller 13.1% YoY on 12.5% revenue growth to Rs2,667.73 Cr - a divergence of more than 3 points from the consolidated decline, stemming from subsidiary-level tax, NCI and associate dynamics that don't touch the parent-only numbers. Neither statement carries an exceptional item this quarter; a year ago the consolidated result had booked a small Rs12.93 Cr one-off gain from the Indore facility sale, so the adjusted YoY PAT decline (~20.5%) is only marginally softer than the reported -22.0%.
Margins compressed on a YoY basis even before the tax effect. Core pre-exceptional profitability (PBT before exceptional items as a share of total income) slipped to 19.83% from 21.62% a year ago, as employee benefits expense rose 16.7% YoY (Rs808.90 Cr vs Rs693.25 Cr) and finance costs nearly doubled (+56.6% YoY, Rs46.62 Cr vs Rs29.78 Cr), both outpacing the 10.95% topline growth. Net margin (PAT/total income) fell to 13.4% from 19.0% YoY. Sequentially, PAT more than doubled (+107.5% QoQ) against Q4 FY26's Rs251.11 Cr, but that base was itself depressed by a Rs134.97 Cr net exceptional charge (a Rs74.7 Cr real-estate impairment provision plus a Rs60.27 Cr gratuity/leave-encashment liability under the new Labour Codes) - so the QoQ jump is a base-effect artefact rather than fresh operating momentum and should not be read as a trend.
We could not find reliable analyst consensus estimates specifically previewing this Q1 FY27 print, so the vs-street read is unknown rather than assumed. Against management's own FY27 outlook from the May 2026 call - a 20-21% margin target, India growth 100-150bps above market, US high-single-digit dollar growth, and ROW higher-teens growth - this filing (single-segment disclosure, no India/US/ROW split) only lets us check the margin line: core pre-exceptional margin of ~19.8% sits just under the guided band, so the quarter reads as broadly on track rather than a clear beat or miss. Alkem issued no accompanying press-release commentary with this filing (none extracted for this result), so there is no fresh management framing to reconcile against the numbers. Two corporate developments bracket this print: Alkem Medtech completed its majority-stake acquisition of Switzerland's Occlutech Holding AG on 16 July 2026 (Note 5) - after the reporting quarter, so it has no impact on these numbers but enters consolidation from Q2 FY27; and a company facility was placed under USFDA OAI status on 6 August 2026, a regulatory flag that doesn't show up in this quarter's P&L but is worth tracking for supply continuity.
Going into Q2 FY27, the key swing factors are whether the ~32% effective tax rate persists as a structural step-change (per Note 4/5) rather than a one-quarter blip, and how quickly employee-cost and finance-cost growth normalise relative to revenue - both will determine whether net-margin trends converge back toward the flatter pretax-margin story or continue to lag it.
